Ashutosh Wechalekar, MBBS, FRCP, FRCPath, University College London Hospitals NHS Trust, London, UK, discusses findings from the Phase III TOURMALINE-AL1 study (NCT01659658), evaluating ixazomib and dexamethasone in the treatment of amyloid light-chain (AL) amyloidosis. This interview was recorded via an online conference call with the Video Journal of Hematological Oncology (VJHemOnc).